EHA2026 Congress: Your CML meeting schedule
As the global hematology community prepares to gather in Stockholm for the European Hematology Association (EHA) 2026 Congress, this year’s program once again highlights the progress in CML research and management.
From June 11–14th, the EHA2026 Congress will feature a range of CML-focused sessions covering emerging therapies, treatment-free remission, mechanisms of disease progression and resistance, blast crisis biology, pediatric CML, and real-world outcomes shaping the future of CML management.
To help you navigate the congress program, we have compiled an overview of CML-related sessions at the EHA2026 Congress.
Read on for some key highlights from this year’s program…
CML Sessions at EHA 2026
Understanding disease progression & blast crisis
- The Specialized Working Group Session on CML (June 12) focuses on blast crisis biology and prediction, including real-world lessons, somatic mutations, chromosomal aberrations, and innovative patient-derived xenograft (PDX) models to guide treatment strategies.
Translational science & treatment optimisation
- The Education Session on CML (June 13) brings together leading experts to discuss the interaction between CML and the bone marrow niche, immune surveillance in treatment-free remission, and how to optimise treatment selection across an expanding therapeutic landscape.
Major oral presentations on CML
This year’s oral sessions on CML on June 11 and June 13 feature important updates from clinical and translational studies, including:
- Long-term ASC4FIRST results evaluating asciminib in newly diagnosed CP-CML
- Treatment-free remission studies including RESTOP and NAUT
- Novel therapeutic treatments and strategies such as ELVN-001 and combination TKI approaches
- New insights into blast crisis initiation, resistance biology, and leukemic stem cell mechanisms
CML poster highlights
EHA2026 also includes a broad range of CML poster presentations addressing:
- Asciminib and olverembatinib clinical experience
- Treatment-free remission strategies
- Pediatric and adolescent CML
- Real-world outcomes and quality-of-life studies
- Novel resistance mechanisms and translational biomarkers
- AI-driven and single-cell approaches in CML biology
There is also a Satellite Symposium on CML supported by Novartis that will take place on June 12 from 10.00 – 11.30 CEST before the start of the official EHA scientific program.
The congress program will be available live and on demand via the EHA2026 platform, which remains accessible until October 15, 2026.
Download the CML session overview here:
View the full EHA2026 Congress program here
As always, the iCMLf will continue to share updates and highlights throughout the Congress, including summaries of important CML presentations.
We look forward to connecting with many of you at EHA2026 either in person or online.
